Taipei, September 17, 2020 – Polaris Group announced today that the first patient has been dosed in a phase 1B trial of ADI‑PEG 20 in combination with Radiotherapy and Temozolomide for the treatment of Newly Diagnosed Glioblastoma Multiforme (GBM). The Lead Investigator is Dr. Wei from Linkou Chang Gung Memorial Hospital. There will be 26 patients enrolled in this phase 1B trial.